Pharmacovirological Impact of an Integrase Inhibitor on Human Immunodeficiency Virus Type 1 cDNA Species In Vivo

Clinical trials of the first approved integrase inhibitor (INI), raltegravir, have demonstrated a drop in the human immunodeficiency virus type 1 (HIV-1) RNA loads of infected patients that was unexpectedly more rapid than that with a potent reverse transcriptase inhibitor, and apparently dose indep...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Goffinet, Christine, Allespach, Ina, Oberbremer, Lena, Golden, Pamela L., Foster, Scott A., Johns, Brian A., Weatherhead, Jason G., Novick, Steven J., Chiswell, Karen E., Garvey, Edward P., Keppler, Oliver T.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society for Microbiology (ASM) 2009
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2708607/
https://ncbi.nlm.nih.gov/pubmed/19458008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.00683-09
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares